RT @doctorRBC: Deucravacitinib TYK2i for PsA Phase2b 16wk, Double-blind, Placebo, RCT ⬆️ACR20/50/70 response vs. PBO
Tweet Content
Deucravacitinib TYK2i for PsA
Phase2b 16wk, Double-blind, Placebo, RCT
⬆️ACR20/50/70 response vs. PBO
⬆️HAQ-DI response, enthesitis resolution, MDA vs. PBO
*⃣No serious AE
@RheumNow #ACR20 Abs#L03 #ACRbest https://t.co/9Klu2aeEj2
Show on Archive Page
On
Display in Search Results
On